Incyte Bets on Drug Pipeline and Deals for Growth After Jakafi Exclusivity Ends

Incyte logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Incyte expects its core business excluding Jakafi to reach $3 billion to $4 billion by 2030. Four pipeline assets—povorcitinib, CALR antibody 989, a G12D inhibitor and latarcibart—could potentially double the company over the long term, executives said.
  • Several programs are advancing: Incyte expects a U.S. approval decision for povorcitinib in hidradenitis suppurativa in Q1 2027, while its G12D inhibitor is in a frontline pancreatic cancer Phase 3 trial. The company also plans additional cancer studies in 2027.
  • To support growth after Jakafi loses exclusivity, Incyte is pursuing deals in hematology, solid tumor oncology and immune-mediated skin conditions. Its estimated deal-making capacity is $7 billion to $8 billion, though executives said it will not necessarily be deployed all at once.
  • MarketBeat previews top five stocks to own in December.

Incyte NASDAQ: INCY is counting on a pipeline of cancer and immunology treatments, along with potential acquisitions, to support growth after JAKAFI loses exclusivity, executives said at the Jefferies Global Healthcare Conference in London.

President and CEO Bill Meury said the company’s core business excluding JAKAFI remains on track to reach approximately $3 billion to $4 billion by 2030. He identified four pipeline assets as potential long-term growth drivers: povorcitinib, CALR antibody 989, a G12D inhibitor and latarcibart. Together, they could double the company over the long term on an unadjusted basis, he said.

CALR Studies and MPN Pipeline

Incyte is running second-line studies of 989 in essential thrombocythemia and myelofibrosis, or MF, and plans to start a frontline study by the middle of 2027, Meury said. The company expects to share frontline data at the upcoming American Society of Hematology meeting.

Meury said Incyte will discuss with the U.S. Food and Drug Administration whether to use a composite endpoint in the frontline MF study. Such an endpoint could incorporate measures including spleen volume, hemoglobin, platelets and blast counts. The company’s base case remains to use conventional endpoints, with a composite as a powered key secondary endpoint if regulators prefer that approach.

Incyte also is developing a next-generation CALR antibody, 798, and a small molecule targeting the JAK2V617F mutation. Meury said the company plans to begin a phase 1 study of the latter in 2027.

G12D and Colorectal Cancer

Meury described Incyte’s G12D inhibitor as a potential major growth driver and said enrollment in its phase 3 frontline pancreatic cancer study is going well. The company plans to start studies in adjuvant pancreatic cancer and second-line colorectal cancer in 2027.

Incyte is also examining combinations intended to produce deeper, more durable responses. Meury said previously shared data from a colorectal cancer study of G12D with an EGFR treatment showed a 36% response rate versus 8% and progression-free survival of about seven months.

Separately, Meury pointed to an experimental TGF-beta and PD-1 treatment for colorectal cancer as a potential outlier opportunity. He said response rates presented at ESMO were encouraging, but progression-free survival will be a key test, with data expected throughout 2027.

Povorcitinib Launch Plans

Meury said Incyte expects a U.S. approval decision in the first quarter of 2027 for povorcitinib in hidradenitis suppurativa, or HS. During the discussion, the analyst said the treatment had received European approval the previous day.

Meury estimated the HS indication could represent a $500 million to $1 billion opportunity. He said Incyte hopes to reach patients both before and after biologic treatment and expects a mix of insurance access arrangements, including some plans requiring a step through biosimilar Humira.

The company also expects data for povorcitinib in prurigo nodularis at year-end and data in vitiligo, Meury said.

Deal-Making Capacity

Chief Strategy Officer Dave Gardner said Incyte’s business development strategy is focused on supporting its growth rate in the 2029 to 2032 period after JAKAFI’s loss of exclusivity. The company is likely to concentrate on hematology, solid tumor oncology and immune-mediated skin conditions, he said.

Gardner estimated Incyte’s deal-making capacity at $7 billion to $8 billion, based on approximately $4 billion in cash and potential borrowing against future cash generation. He said the company is unlikely to deploy that capacity all at once and is seeking transactions similar to its previously announced Star Vega deal.

“The only thing worse than doing no deals would be doing the wrong deal,” Gardner said, adding that Incyte remains active and engaged in pursuing opportunities.

About Incyte (NASDAQ:INCY)

Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally. Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Incyte Right Now?

Before you consider Incyte, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Incyte wasn't on the list.

While Incyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines